EGFR and lung carcinoma: For example, acquired resistance to first and second-generation EGFR inhibitors in lung cancer can be conferred by point mutations such EGFR T790M mutation and resistance to third-generation EGFR inhibitors can be conferred by EGFR C797S mutation [3].